¼¼°èÀÇ ºñÈæ»öÁ¾ ÇÇºÎ¾Ï Ä¡·á ½ÃÀå º¸°í¼­ : Ä¡·á À¯Çü, ÀûÀÀÁõ, ÃÖÁ¾ ¿ëµµ, Áö¿ªº°(2024-2032³â)
Non-Melanoma Skin Cancer Treatment Market Report by Treatment Type, Indication, End Use, and Region 2024-2032
»óǰÄÚµå : 1541189
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 144 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,339,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,786,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,233,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ºñÈæ»öÁ¾ ÇÇºÎ¾Ï Ä¡·á(NMSC, Non-Melanoma Skin Cancer Treatment) ½ÃÀå ±Ô¸ð´Â 2023³â 5¾ï 6,320¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC ±×·ìÀº ÇâÈÄ ½ÃÀåÀÌ 2032³â±îÁö 8¾ï 5,010¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇßÀ¸¸ç, 2024³â°ú 2032³â »çÀÌ¿¡ 4.5%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

ºñÈæ»öÁ¾ ÇǺξÏ(NMSC)Àº ÇǺÎÀÇ »óÃþºÎ¿¡¼­ ¾Ç¼º ¼¼Æ÷ÀÇ ÀÌ»ó Áõ½ÄÀ» ¸»ÇÕ´Ï´Ù. NMSCÀÇ ÀϹÝÀûÀÎ À¯ÇüÀ¸·Î´Â ±âÀú¼¼Æ÷¾Ï, ¸ÓŬ¼¼Æ÷¾Ï, ÆíÆò»óÇǾÏ, ÇǺΠT¼¼Æ÷ ¸²ÇÁÁ¾ µîÀÌ ÀÖ½À´Ï´Ù. ÁÖ·Î ÇǺο¡ µüµüÇÑ ¸ÕÁö¿Í ºñ´Ã ¸ð¾çÀÇ ¹ÝÁ¡ÀÌ »ý±â´Â °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. Ä¡·á ¼ö¹ýÀ¸·Î´Â Çö¹Ì°æ ¼ö¼ú, ·¹ÀÌÀú Ä¡·á, µ¿°á ¿ä¹ý µîÀÇ ¿Ü°úÀû óġ¿¡ ÀÇÇÑ ¾Ï¼¼Æ÷ÀÇ Á¦°Å³ª ±¤¼±¿ªÇÐÀû ¿ä¹ý(PDT), ¹æ»ç¼±Ä¡·á, Àü±âÄ¡·á µî ´Ù¾çÇÑ ºñ¼ö¼úÀû Ä¡·á°¡ ÀÖ½À´Ï´Ù.

ÇǺξÏÀÇ À¯º´·ü Áõ°¡¿Í ¼¼°è ³ëÀÎ Àα¸ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, NMSC¿¡ ´ëÇÑ À̿밡´ÉÇÑ ´ëü Ä¡·á¹ý¿¡ ´ëÇÑ ´ëÁßÀÇ ÀÇ½Ä Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ÀüÅëÀûÀ¸·Î »ç¿ëµÇ´Â Ä¡·á¹ý°ú ºñ±³ÇÒ ¶§, Ç¥À缺 ¹æ»ç¼± ¿ä¹ýÀº ȯÀÚÀÇ ½Åü¿¡ ºÎÀÛ¿ëÀÌ Àû°í Çõ½ÅÀûÀÎ ÈÞ´ë¿ë Àåºñ¸¦ »ç¿ëÇÏ¿© ¼öÇà ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ Àåºñ´Â ³ôÀº Á¤È®µµ¿Í °¨µµ·Î ÇǺΠº´º¯ÀÇ Á¶±â Áø´Ü¿¡µµ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ ÀüÀں귢¼¼¶óÇÇ(eBx)ÀÇ °³¹ß µî ´Ù¾çÇÑ ±â¼ú Áøº¸µµ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. eBx´Â ÅëÁõÀÌ ¾ø´Â ºñħ½ÀÀûÀΠǥÀû Àú¿¡³ÊÁö ¹æ»ç¼± ¿ä¹ýÀ̸ç, Ä¡·á ±â°£ÀÌ Âª°í, ÀÌ¿ô °Ç°­ÇÑ Á¶Á÷¿¡ ´ëÇÑ ¹æ»ç¼± ³ëÃâÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× ¹ÛÀÇ ¿äÀÎÀ¸·Î´Â °³ÀÎÀÇ ÇコÄɾî ÁöÃâ Áõ°¡, ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø, ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿ µîÀÌ ½ÃÀåÀ» ´õ¿í °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§ ¹× Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ºñÈæ»öÁ¾ ÇÇºÎ¾Ï Ä¡·á ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : Ä¡·á À¯Çüº°

Á¦7Àå ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°

Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ ¿ëµµº°

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦10Àå SWOT ºÐ¼®

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global non-melanoma skin cancer treatment market size reached US$ 563.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 850.1 Million by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032.

Non-melanoma skin cancer (NMSC) refers to the abnormal growth of malignant cells in the upper layer of the skin. Some of the common types of NMSC include basal cell, merkle cell and squamous cell carcinoma and cutaneous T-cell lymphoma. It is primarily characterized by the development of firm lumps or scaly patches on the skin. The treatment methodologies involve the removal of cancer cells through surgical procedures, including micrographic surgery, laser therapy and cryotherapy, and various non-surgical treatments, such as photodynamic therapy (PDT), radiotherapy and electrotherapy.

The increasing prevalence of skin cancer and the rising geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available treatment alternatives for NMSC is also stimulating the market growth. In comparison to the traditionally used therapies, superficial radiation therapy has reduced side-effects on the patient's body and can be conducted through innovative portable devices. These devices are also used for early diagnosis of skin lesions with high accuracy and sensitivity. Additionally, various technological advancements, such as the development of electronic brachytherapy (eBx), are acting as other growth-inducing factors. eBx is a painless and non-invasive targeted low-energy radiation therapy that requires a shorter treatment course and minimizes the risks of radiation exposure to the nearby healthy tissues. Other factors, including rising healthcare expenditures of individuals and government funding for clinical trials, along with extensive research and development (R&D) activities, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global non-melanoma skin cancer treatment market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on treatment type, indication and end use.

Breakup by Treatment Type:

Chemotherapy

Radiation Therapy

Photodynamic Therapy

Others

Breakup by Indication:

Basal Cell Carcinoma

T-Cell Lymphoma

Squamous Cell Carcinoma

Others

Breakup by End Use:

Hospitals

Specialty Clinics

Ambulatory Surgery Centers

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Icad Inc., Merck & Co. Inc., Novartis AG, Sun Pharmaceutical Industries Limited and Varian Medical Systems Inc.

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Non-Melanoma Skin Cancer Treatment Market

6 Market Breakup by Treatment Type

7 Market Breakup by Indication

8 Market Breakup by End Use

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â